ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 668

Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?

Michelle Lopes1, Samara Gavinier2, Elaine Leon2, Vilma Viana2, Eduardo Ferreira Borba1 and Eloisa Bonfa3, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, 3Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, Lupus nephritis, outcomes and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Hyperuricemia has been reported to be associated with chronic kidney disease (CKD) in several clinical conditions, and recent studies also observed an association between increased uric acid (UA) serum levels and renal damage in lupus. However, the predictive value of UA for the development of long-term renal dysfunction in lupus nephritis is unknown. The purpose of this study was to evaluate if the UA level may be considered a predictor of long-term renal outcome in patients with lupus nephritis.

Methods: 75 biopsy-proven lupus nephritis patients with more than 7 years follow-up were consecutively selected for this study. Clinical and laboratorial data were obtained using a standardized electronic chart database protocol carried out at 1-6 months interval. UA levels were measured in sera stored at -70ºC for all SLE patients at biopsy during nephritis flare and in 31 patients, for whom sera were available, at 6 and 12 months post-biopsy. The renal outcome was addressed after 7 years of follow-up to determine if UA was a predictor of good long-term renal outcome (Cr<1.5mg/dL in 7 years). SLE patients were divided in two groups according to the renal outcome [good outcome (Cr<1.5mg/dL in 7 years) and poor outcome (Cr≥1.5mg/dL in 7 years)] to assess whether UA levels at different time-points of follow-up were able to differentiate such groups. ROC curves were plotted to assess UA accuracy.

Results: At baseline, patients had mean SCr of 1.7±1.3 mg/dl, proteinuria of 5.7±4.7 g/24h, albumin of 2.4±0.8 g/dl, and SLEDAI scores of 9.5±5.0. Almost two thirds of the patients (66%) patients had positive anti-dsDNA and 28 patients (35%) had SCr≥1.5mg/dl. The distribution of histological classes among studied patients was: class II (6%), class III / IV (53%) and pure class V (36%). Serum UA levels were not able to differentiate good from poor long-term renal outcomes in patients with lupus nephritis at any of the time points analyzed: baseline, 6, 12 months (respectively p = 0.96, p = 0.76, p = 0.77). As expected, the ROC curve with higher AUC (12 months) showed a low accuracy (AUC=0.59). The cut-off for UA was 5.46mg/dL (Sensitivity=0.63, Specificity= 0.65, Positive Predictive Value=0.38, Negative Predictive Value=0.16, 95% CI=0.2-0.7, p<0.05). The AU was only associated with the current creatinine levels: at baseline (p=0.01), 6 months (p=0.03) and 12 months (p=0.01).

Conclusion: This study demonstrated that serum uric acid levels in lupus patients reflect solely the current renal function and it is not a good predictor of long-term renal outcome in lupus nephritis.


Disclosure: M. Lopes, None; S. Gavinier, None; E. Leon, None; V. Viana, None; E. F. Borba, None; E. Bonfa, None, 2.

To cite this abstract in AMA style:

Lopes M, Gavinier S, Leon E, Viana V, Borba EF, Bonfa E. Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/is-uric-acid-level-a-predictor-of-long-term-renal-outcome-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-uric-acid-level-a-predictor-of-long-term-renal-outcome-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology